Pacira BioSciencesPCRX.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, Pacira BioSciences (PCRX.O) trades at a P/E of 99.00x, P/B of 2.16x, P/S of 1.94x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 63rd percentile over the trailing 10Y window (vs. 65th percentile over 3Y); P/B sits at the 32nd percentile over the trailing 10Y window (vs. 100th percentile over 3Y); P/S sits at the 25th percentile over the trailing 10Y window (vs. 82nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 92nd percentile within its industry and the 93rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 10.23%, ranking at the 95th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 31.4 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. Pacira BioSciences operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: PCRX · PCRX
Want the full picture on whether Pacira BioSciences (PCRX.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 99.00 | ||||||
| P/B (MRQ) | 2.16 | ||||||
| P/S (TTM) | 1.94 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 10.23% |